Edelfosine (ET-18-OCH3) is an orally effective lipid raft modulator and apoptosis (Apoptosis) inducer that alters membrane fluidity and preferentially inserts into tumor cell membranes. Edelfosine recruits death receptor ligands (FasL/CD95L, TRAIL) and Bid to lipid rafts to form death-inducing signaling complexes, thereby initiating mitochondria-dependent apoptosis and inducing cytochrome c release. Edelfosine also exerts anti-inflammatory effects, promotes L-Selectin shedding, and causes no gastrointestinal or organ toxicity. In addition, Edelfosine inhibits nucleic acid and protein synthesis in Leishmania donovani and exhibits antiproliferative activity. Edelfosine can be used in research on multiple myeloma, inflammatory bowel diseases (such as ulcerative colitis and Crohns disease), and visceral leishmaniasis[1][2][3][4].
Molekulargewicht:
523.73
Reinheit:
99
CAS Nummer:
[70641-51-9]
Formel:
C27H58NO6P
Target-Kategorie:
Apoptosis,Bcl-2 Family,Cytochrome P450,Parasite
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
